The Biomarkers Oncologists Need to Know for Personalized Cancer Care in 2019

The Biomarkers Oncologists Need to Know for Personalized Cancer Care in 2019 (June 2019)

Saturday, June 1, 2019
Webinar -- 7:00 PM CT

Agenda

7:00 PM – 7:05 PM  Program Overview Program Chair

7:05 PM – 7:25 PM  Integrating MMRd/MSI Testing for Patients with Solid Tumors

7:25 PM – 7:45 PM  PD-L1 to Guide Therapy in the Clinic: Current Indications

7:45 PM – 8:05 PM  The Evolving Role of BRCA and Defective DNA Damage Repair in Cancer Care

8:05 PM – 8:25 PM Current Indications and Future Directions for Targets Affecting Cellular Communication and Survival

8:25 PM – 8:45 PM  Novel Therapeutically Actionable Targets in Cell Signaling For Expanded Treatment Options

8:45 PM – 9:00 PM Conclusions and Audience Question & Answer Session

Faculty

Program Director
John L. Marshall, MD

Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Faculty
Todd M. Bauer, MD

Associate Director, Drug Development
Sarah Cannon Research Institute
Tennessee Oncology, PLLC
Nashville, Tennessee

Faculty
Axel Grothey, MD

Director of GI Cancer Research
West Cancer Center and Research Institute
Germantown, Tennessee

Faculty
Michael J. Pishvaian, MD, PhD

Phase I Program Director
Medical Director of the CRMO
Associate Professor

Lombardi Comprehensive Cancer Center
Washington, DC

Faculty
David R. Spigel, MD

Chief Scientific Officer
Director,
Lung Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Goal Statement
The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating biomarkers to personalize cancer care.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with cancer.

Learning Objectives 

  • Apply predictive biomarkers to guide therapeutic decisions in patients with cancer
  • Evaluate the available data and expert recommendations to determine which biomarkers should be tested in your patients with cancer
  • Explain to patients the need for an additional biopsy to test for appropriate biomarkers in cases where the initial biopsy sample was insufficient or if the biomarker status was previously unknown
  • Evaluate the available next-generation sequencing and comprehensive genomic profiling diagnostic assays
  • Identify patients eligible to enroll on important ongoing clinical trials based on molecular testing of their tumor

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation
CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.